Alumis (NASDAQ:ALMS) Stock Gets Price Target Reduction from HC Wainwright

Alumis (NASDAQ:ALMS – Free Report) had its price target trimmed by HC Wainwright from $15.00 to $9.00 in a report released on Friday morning,Benzinga reports. The firm currently has a buy rating on the stock.

Other research analysts have also issued reports about the company. Citigroup reiterated an “overweight” rating on shares of Alumis in a research note on Tuesday, September 1st. Oppenheimer reduced their target price on shares of Alumis from $55.00 to $37.00 and set an “outperform” rating on the stock in a research note on Wednesday, September 2nd. Wells Fargo & Company reduced their target price on shares of Alumis from $51.00 to $25.00 and set an “overweight” rating on the stock in a research note on Wednesday, September 2nd. Robert W. Baird set a $27.00 target price on shares of Alumis in a research report on Tuesday, September 1st. Finally, Morgan Stanley cut their price target on shares of Alumis from $39.00 to $29.00 and set an “overweight” rating for the company in a report on Wednesday, September 2nd. One equities research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $32.09.

View Our Latest Analysis on Alumis

Alumis Stock Performance

Shares of ALMS opened at $5.60 on Friday. Alumis has a 1 year low of $4.60 and a 1 year high of $31.35. The stock has a 50 day simple moving average of $7.24 and a 200-day simple moving average of $20.46. The stock has a market cap of $724.84 million, a PE ratio of -1.59 and a beta of -0.28.

Alumis (NASDAQ:ALMS – Get Free Report) last posted its earnings results on Thursday, November 12th. The company reported ($0.73) EPS for the quarter, topping the consensus estimate of ($0.76) by $0.03. The business had revenue of $1.91 million during the quarter, compared to the consensus estimate of $1.90 million. Alumis had a negative return on equity of 89.77% and a negative net margin of 5,844.54%. On average, sell-side analysts forecast that Alumis will post -2.95 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director Srinivas Akkaraju sold 96,131 shares of the firm’s stock in a transaction on Tuesday, September 8th. The stock was sold at an average price of $10.55, for a total transaction of $1,014,182.05. Following the completion of the sale, the director directly owned 2,025,493 shares of the company’s stock, valued at $21,368,951.15. This trade represents a 4.53% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Over the last ninety days, insiders sold 99,754 shares of company stock worth $1,037,804. Company insiders own 33.70% of the company’s stock.

Institutional Trading of Alumis

Large investors have recently made changes to their positions in the business. Marshall Wace LLP increased its stake in shares of Alumis by 188.7% in the third quarter. Marshall Wace LLP now owns 1,062,571 shares of the company’s stock valued at $7,852,000 after buying an additional 694,557 shares in the last quarter. Healthcare of Ontario Pension Plan Trust Fund bought a new position in shares of Alumis in the third quarter valued at about $706,000. Polymer Capital Management US LLC bought a new position in shares of Alumis in the third quarter valued at about $152,000. First Trust Advisors LP lifted its position in Alumis by 244.8% during the 3rd quarter. First Trust Advisors LP now owns 324,311 shares of the company’s stock worth $2,397,000 after buying an additional 230,265 shares in the last quarter. Finally, Ieq Capital LLC acquired a new position in Alumis during the 3rd quarter worth about $306,000.

Alumis News Summary

Here’s some of the latest news about ALMS:

  • Positive Sentiment: Alumis reported new Phase 3 data showing rapid, durable improvements in plaque psoriasis. The company said envudeucitinib had the highest publicly reported Week 48 PASI 100 response rate among existing and investigational oral psoriasis therapies, reinforcing its potential clinical differentiation. Alumis Q3 2026 financial results and business updates
  • Neutral Sentiment: Q3 adjusted performance was slightly better than expected: the loss was $0.73 per share versus the $0.76 consensus, while revenue of $1.91 million was essentially in line with estimates of $1.90 million. The small beat is tempered by continued losses. Alumis earnings results
  • Negative Sentiment: Wells Fargo cut its price target to $18 from $25, and HC Wainwright lowered its target to $9 from $15. Both firms kept bullish ratings—Overweight and Buy, respectively—but the reductions may signal more cautious expectations and pressure the stock. Wells Fargo price target report

Alumis Company Profile

(Get Free Report)

Alumis is a clinical-stage biopharmaceutical company developing medicines for autoimmune and inflammatory diseases. The company uses data and computational tools to support the discovery and development of targeted treatments. Its lead investigational program, ESK-001, is an oral, selective TYK2 inhibitor being studied for conditions including plaque psoriasis and systemic lupus erythematosus. Alumis is also advancing other drug candidates for immune-mediated diseases. These medicines remain in clinical development and are not approved for commercial use.

Recommended Stories

Analyst Recommendations for Alumis (NASDAQ:ALMS)

Receive News & Ratings for Alumis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alumis and related companies with MarketBeat.com's FREE daily email newsletter.